Table 4 One year atropine 0.01% treatment clinical trials and studies results overview.
From: A multicenter Spanish study of atropine 0.01% in childhood myopia progression
Ethnicity | Country | Design | Recruited children (n) | Included children per group [n, (group)]* | Age (mean ± SD, years) | SE at baseline (mean ± SD, D) | AL at baseline (mean ± SD, mm) | SE change in the previous year (mean ± SD, D) | After 1 year treatment | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SE change (mean ± SD, D) | AL change (mean ± SD, mm) | SE relative reduction (%) | Progression < − 0.5D (% patients) | |||||||||
Asian studies | ||||||||||||
Chia 2012 ATOM 2 (Phase 1) | Singapore | Clinical Trial | 400 | 75 (A) | 9.5 ± 1.5 | − 4.5 ± 1.5 | 25.2 ± 1.0 | − 0.43 ± 0.52 | 0.24 ± 0.19 | 50 | ||
0 (C) | ||||||||||||
Yam 2019 LAMP (Phase 1) | Hong Kong (China) | Clinical Trial | 438 | 97 (A) | 8.23 ± 1.83 | − 3.77 ± 1.85 | 24.70 ± 0.99 | − 0.81 ± 0.32 | − 0.59 ± 0.61 | 0.36 ± 0.29 | 27.2 | 43.8 |
93 (C) | 8.42 ± 1.72 | − 3.85 ± 1.95 | 24.82 ± 0.97 | − 0.88 ± 0.36 | − 0.81 ± 0.53 | 0.41 ± 0.22 | 27.2 | |||||
Wei, 2020 | China | Clinical Trial | 220 | 76 (A) | 9.44 ± 1.80 | − 2.52 ± 1.33 | 24.50 ± 0.76 | − 0.49 ± 0.42 | 0.32 ± 0.19 | 34.2 | 48.7 | |
83 (C) | 9.84 ± 1.53 | − 2.64 ± 1.46 | 24.69 ± 0.97 | − 0.76 ± 0.50 | 0.41 ± 0.19 | |||||||
Fu, 2020 | China | Clinical Trial | 400 | 142 (A) | 9.3 ± 1.9 | − 2.70 ± 1.64 | 24.58 ± 0.74 | − 0.47 ± 0.45D | 0.37 ± 0.22 | 32.8 | 45.1 | |
120 (C) | 9.5 ± 1.4 | − 2.68 ± 1.42 | 24.55 ± 0.71 | − 0.70 ± 0.60D | 0.46 ± 0.35 | |||||||
Non Asian studies | ||||||||||||
Larkin 2019 | USA | Retrospective Multicenter | 198 | 100 (A) | 9.3 ± 2.10 | − 3.1 ± 1.9 | − 0.2 ± 0.8 | |||||
98 (C) | 9.2 ± 2.11 | − 2.8 ± 1.6 | − 0.6 ± 0.4 | 66.6 | ||||||||
Sacchi 2019 | Italy | Retrospective | 102 | 52 (A) | 9.7 ± 2.3 | − 3 ± 2.23 | − 1.20 ± 0.64 | − 0.54 ± 0.61 | 55 | 79 | ||
50 (C) | 12.1 ± 2.9 | − 2.63 ± 2.68 | − 0.80 ± 0.64 | − 1.09 ± 0.64 | 50.5 | |||||||
Clark 2015 | USA | Retrospective | 60 | 32 (A) | 10.2 ± 2.2 | − 2.0 ± 1.6 | − 0.1 ± 0.6 | 83.3 | ||||
28 (C) | 10.2 ± 2.2 | − 2.0 ± 1.5 | − 0.6 ± 0.4 | |||||||||
Joachimsen 2019 | Germany | Retrospective | 56 | 56 (A) | 11 | − 3.85 ± 1.88 | − 1.05 ± 0.37 | − 0.40 ± 0.49 | 65 | |||
0 (C) | ||||||||||||
Pérez 2021 GTAM | Spain | Prospective Multicenter | 105 | 92 (A) | 9.76 ± 1.93 | − 3.56 ± 1.12 | 24.57 ± 0.79 | − 1.01 ± 0.38 | − 0.44 ± 0.41 | 0.27 ± 0.20 | 56.43 | 62 |
0 (C) | ||||||||||||
